NASDAQ:OTLK - Outlook Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.10 0.00 (0.00 %) (As of 02/22/2019 04:00 PM ET)Previous Close$1.10Today's Range$1.06 - $1.1352-Week Range$0.20 - $1.37Volume132,417 shsAverage Volume664,654 shsMarket Capitalization$103.04 millionP/E RatioN/ADividend YieldN/ABeta1.62 ProfileDiscussionChartEarningsInsider TradesHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases. The company has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in December 2018. The company was founded in 2010 and is headquartered in Cranbury, New Jersey. Receive OTLK News and Ratings via Email Sign-up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OTLK Previous Symbol CUSIPN/A CIKN/A Webwww.outlooktherapeutics.com Phone609-619-3990Debt Debt-to-Equity RatioN/A Current Ratio0.08 Quick Ratio0.08Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.09 million Price / Sales33.35 Cash FlowN/A Price / Cash FlowN/A Book Value($0.28) per share Price / Book-3.93Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-30,090,000.00 Net Margins-1,121.35% Return on EquityN/A Return on Assets-131.93%Miscellaneous Employees56 Outstanding Shares93,670,000Market Cap$103.04 million Next Earnings Date5/21/2019 (Estimated) OptionableNot Optionable Outlook Therapeutics (NASDAQ:OTLK) Frequently Asked Questions What is Outlook Therapeutics' stock symbol? Outlook Therapeutics trades on the NASDAQ under the ticker symbol "OTLK." How were Outlook Therapeutics' earnings last quarter? Outlook Therapeutics, Inc. (NASDAQ:OTLK) posted its earnings results on Thursday, February, 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.21. The company earned $1.07 million during the quarter. View Outlook Therapeutics' Earnings History. When is Outlook Therapeutics' next earnings date? Outlook Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, May 21st 2019. View Earnings Estimates for Outlook Therapeutics. Has Outlook Therapeutics been receiving favorable news coverage? News coverage about OTLK stock has trended somewhat positive recently, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Outlook Therapeutics earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. Who are some of Outlook Therapeutics' key competitors? Some companies that are related to Outlook Therapeutics include Harpoon Therapeutics (HARP), Nightstar Therapeutics (NITE), Translate Bio (TBIO), Gritstone Oncology (GRTS), Agenus (AGEN), MeiraGTx (MGTX), CASI Pharmaceuticals (CASI), Gamida Cell (GMDA), Avrobio (AVRO), Cellular Biomedicine Group (CBMG), Krystal Biotech (KRYS), Solid Biosciences (SLDB), Eiger Biopharmaceuticals (EIGR), Sutro Biopharma (STRO) and Adverum Biotechnologies (ADVM). What other stocks do shareholders of Outlook Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Outlook Therapeutics investors own include United States Brent Oil Fund (BNO), Aphria (APHA), Kirkland Lake Gold (KL), DHI Group (DHX), NVIDIA (NVDA), National Bank of Canada (NA), Velocity Data (VCT), Rent-A-Center (RCII), AAR (AIR) and Lendlease Group (LLC). Who are Outlook Therapeutics' key executives? Outlook Therapeutics' management team includes the folowing people: Mr. Lawrence A. Kenyon, Pres, CEO, CFO, Company Sec.,Treasurer & Director (Age 53)Dr. Pankaj Mohan, Founder & Director (Age 54)Dr. Kenneth M. Bahrt, Chief Medical Officer (Age 66)Mr. Terry Dagnon, Chief Operating Officer (Age 58)Rick Gregory, Director of Marketing & Communications How do I buy shares of Outlook Therapeutics? Shares of OTLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Outlook Therapeutics' stock price today? One share of OTLK stock can currently be purchased for approximately $1.10. How big of a company is Outlook Therapeutics? Outlook Therapeutics has a market capitalization of $103.04 million and generates $3.09 million in revenue each year. Outlook Therapeutics employs 56 workers across the globe. What is Outlook Therapeutics' official website? The official website for Outlook Therapeutics is http://www.outlooktherapeutics.com. How can I contact Outlook Therapeutics? Outlook Therapeutics' mailing address is 7 CLARKE DRIVE, CRANBURY NJ, 08512. The company can be reached via phone at 609-619-3990 or via email at [email protected] MarketBeat Community Rating for Outlook Therapeutics (NASDAQ OTLK)Community Ranking: 1.7 out of 5 ()Outperform Votes: 12 (Vote Outperform)Underperform Votes: 23 (Vote Underperform)Total Votes: 35MarketBeat's community ratings are surveys of what our community members think about Outlook Therapeutics and other stocks. Vote "Outperform" if you believe OTLK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OTLK will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/23/2019 by MarketBeat.com StaffFeatured Article: How can investors find ex-dividend dates?